In vitro interactions between amphotericin B and hydrocortisone: Potential implications for intrathecal therapy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fungal meningitis remains a severe and often lethal infection requiring aggressive antifungal therapy and in refractory cases the use of intrathecal amphotericin B (AmB). Administration of amphotericin B by this method may result in clinically apparent adverse reactions such as paresthesias, radiculitis, or myelopathy. Coadministration of hydrocortisone is therefore often given in an attempt to avoid these effects; however, the potential consequences of this approach on fungal growth or on drug synergy/antagonism had not previously been assessed. We used the checkerboard titration broth microdilution method to analyze interactions by fractional inhibitory concentration indices (FICIs). The combination of amphotericin B and hydrocortisone resulted in synergy or indifference against all isolates (Candida, Cryptococcus, and Coccidioides) during in vitro testing at low concentrations. Antagonism was observed using higher hydrocortisone concentrations (those not observed in vivo) suggesting possible steric hindrance or binding to AmB may occur at doses unlikely to be present during clinical care. Concurrent hydrocortisone and AmB administration should not be avoided due to in vitro antagonism concerns.

Original languageEnglish (US)
Pages (from-to)749-753
Number of pages5
JournalMedical Mycology
Volume53
Issue number7
DOIs
StatePublished - Jun 2 2015

Fingerprint

amphotericin B
Amphotericin B
cortisol
Hydrocortisone
therapeutics
drug synergism
Fungal Meningitis
Drug Antagonism
Coccidioides
Therapeutics
Cryptococcus
Radiculopathy
Paresthesia
Spinal Cord Diseases
meningitis
minimum inhibitory concentration
Candida
titration
microbial growth
In Vitro Techniques

Keywords

  • amphotericin B
  • Candida
  • Coccidioides
  • coccidioidomycosis
  • Cryptococcus
  • hydrocortisone
  • intrathecal therapy
  • meningitis
  • refractory

ASJC Scopus subject areas

  • veterinary(all)
  • Infectious Diseases

Cite this

@article{fcc65b6ef29247799f6ce4b6d506a2a1,
title = "In vitro interactions between amphotericin B and hydrocortisone: Potential implications for intrathecal therapy",
abstract = "Fungal meningitis remains a severe and often lethal infection requiring aggressive antifungal therapy and in refractory cases the use of intrathecal amphotericin B (AmB). Administration of amphotericin B by this method may result in clinically apparent adverse reactions such as paresthesias, radiculitis, or myelopathy. Coadministration of hydrocortisone is therefore often given in an attempt to avoid these effects; however, the potential consequences of this approach on fungal growth or on drug synergy/antagonism had not previously been assessed. We used the checkerboard titration broth microdilution method to analyze interactions by fractional inhibitory concentration indices (FICIs). The combination of amphotericin B and hydrocortisone resulted in synergy or indifference against all isolates (Candida, Cryptococcus, and Coccidioides) during in vitro testing at low concentrations. Antagonism was observed using higher hydrocortisone concentrations (those not observed in vivo) suggesting possible steric hindrance or binding to AmB may occur at doses unlikely to be present during clinical care. Concurrent hydrocortisone and AmB administration should not be avoided due to in vitro antagonism concerns.",
keywords = "amphotericin B, Candida, Coccidioides, coccidioidomycosis, Cryptococcus, hydrocortisone, intrathecal therapy, meningitis, refractory",
author = "Greg Hodge and Cohen, {Stuart H} and Thompson, {George Richard}",
year = "2015",
month = "6",
day = "2",
doi = "10.1093/mmy/myv047",
language = "English (US)",
volume = "53",
pages = "749--753",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - In vitro interactions between amphotericin B and hydrocortisone

T2 - Potential implications for intrathecal therapy

AU - Hodge, Greg

AU - Cohen, Stuart H

AU - Thompson, George Richard

PY - 2015/6/2

Y1 - 2015/6/2

N2 - Fungal meningitis remains a severe and often lethal infection requiring aggressive antifungal therapy and in refractory cases the use of intrathecal amphotericin B (AmB). Administration of amphotericin B by this method may result in clinically apparent adverse reactions such as paresthesias, radiculitis, or myelopathy. Coadministration of hydrocortisone is therefore often given in an attempt to avoid these effects; however, the potential consequences of this approach on fungal growth or on drug synergy/antagonism had not previously been assessed. We used the checkerboard titration broth microdilution method to analyze interactions by fractional inhibitory concentration indices (FICIs). The combination of amphotericin B and hydrocortisone resulted in synergy or indifference against all isolates (Candida, Cryptococcus, and Coccidioides) during in vitro testing at low concentrations. Antagonism was observed using higher hydrocortisone concentrations (those not observed in vivo) suggesting possible steric hindrance or binding to AmB may occur at doses unlikely to be present during clinical care. Concurrent hydrocortisone and AmB administration should not be avoided due to in vitro antagonism concerns.

AB - Fungal meningitis remains a severe and often lethal infection requiring aggressive antifungal therapy and in refractory cases the use of intrathecal amphotericin B (AmB). Administration of amphotericin B by this method may result in clinically apparent adverse reactions such as paresthesias, radiculitis, or myelopathy. Coadministration of hydrocortisone is therefore often given in an attempt to avoid these effects; however, the potential consequences of this approach on fungal growth or on drug synergy/antagonism had not previously been assessed. We used the checkerboard titration broth microdilution method to analyze interactions by fractional inhibitory concentration indices (FICIs). The combination of amphotericin B and hydrocortisone resulted in synergy or indifference against all isolates (Candida, Cryptococcus, and Coccidioides) during in vitro testing at low concentrations. Antagonism was observed using higher hydrocortisone concentrations (those not observed in vivo) suggesting possible steric hindrance or binding to AmB may occur at doses unlikely to be present during clinical care. Concurrent hydrocortisone and AmB administration should not be avoided due to in vitro antagonism concerns.

KW - amphotericin B

KW - Candida

KW - Coccidioides

KW - coccidioidomycosis

KW - Cryptococcus

KW - hydrocortisone

KW - intrathecal therapy

KW - meningitis

KW - refractory

UR - http://www.scopus.com/inward/record.url?scp=84941254693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941254693&partnerID=8YFLogxK

U2 - 10.1093/mmy/myv047

DO - 10.1093/mmy/myv047

M3 - Article

C2 - 26162473

AN - SCOPUS:84941254693

VL - 53

SP - 749

EP - 753

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 7

ER -